

RESEARCH ARTICLE

# LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project

Francisca A. de Leeuw<sup>1</sup> | Betty M. Tijms<sup>1</sup> | Astrid S. Doorduijn<sup>1,2</sup> |  
Heleen M. A. Hendriksen<sup>1</sup> | Ondine van de Rest<sup>3</sup> | Marian A. E. de van der Schueren<sup>4</sup> |  
Marjolein Visser<sup>5</sup> | Ellen G. H. M. van den Heuvel<sup>6</sup> | Nick van Wijk<sup>7</sup> | Jörgen Bierau<sup>8</sup> |  
Bart N. van Berckel<sup>9</sup> | Philip Scheltens<sup>1</sup> | Maartje I. Kester<sup>10</sup> | Wiesje M. van der  
Flier<sup>1,11</sup> | Charlotte E. Teunissen<sup>12</sup>

<sup>1</sup> Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands

<sup>2</sup> Department of Nutrition and Dietetics, Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands

<sup>3</sup> Division of Human Nutrition and Health, Wageningen University and Research, Wageningen, the Netherlands

<sup>4</sup> Department of Nutrition and Health, HAN University of Applied Sciences, Nijmegen, the Netherlands

<sup>5</sup> Department of Health Sciences, Faculty of Science, Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

<sup>6</sup> FrieslandCampina, Amersfoort, the Netherlands

<sup>7</sup> Danone Nutricia Research, Utrecht, the Netherlands

<sup>8</sup> Department of Clinical Genetics, Maastricht UMC+, Maastricht, the Netherlands

<sup>9</sup> Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands

<sup>10</sup> Department of Neurology, Flevoziekenhuis, Almere, the Netherlands

<sup>11</sup> Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands

<sup>12</sup> Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands

## Correspondence

Francisca A. de Leeuw, Department of Neurology and Alzheimer Center, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan, 1118, 1081 HZ, Amsterdam, The Netherlands.  
Email: f.deleeuw@amsterdamumc.nl

## Abstract

**INTRODUCTION:** We examined associations between nutritional biomarkers and clinical progression in individuals with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and Alzheimer's disease (AD)-type dementia.

**METHODS:** We included 528 individuals ( $64 \pm 8$  years, 46% F, follow-up  $2.1 \pm 0.87$  years) with SCD ( $n = 204$ ), MCI ( $n = 130$ ), and AD ( $n = 194$ ). Baseline levels of cholesterol, triglycerides, glucose, homocysteine, folate, vitamin A, B12, E and uridine were measured in blood and S-adenosylmethionine and S-adenosylhomocysteine in cerebrospinal fluid. We determined associations between nutritional biomarkers and clinical progression using Cox proportional hazard models.

**RESULTS:** Twenty-two (11%) patients with SCD, 45 (35%) patients with MCI, and 100 (52%) patients with AD showed clinical progression. In SCD, higher levels of

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* published by Wiley Periodicals, LLC on behalf of Alzheimer's Association

low-density lipoprotein (LDL) cholesterol were associated with progression (hazard ratio [HR] [95% confidence interval (CI)] 1.88 [1.04 to 3.41]). In AD, lower uridine levels were associated with progression (0.79 [0.63 to 0.99]).

**DISCUSSION:** Our findings suggest that LDL cholesterol and uridine play a—stage-dependent—role in the clinical progression of AD.

#### KEYWORDS

Alzheimer's disease, cholesterol, clinical progression, memory clinic, nutritional biomarkers, uridine

## 1 | BACKGROUND

Changes in nutritional status including weight loss and lower nutrient levels are often prevalent before the onset of Alzheimer's disease (AD)-type dementia.<sup>1–4</sup> Impaired nutritional status has been associated with faster cognitive decline in community-based populations.<sup>5–7</sup> Nutritional biomarker levels in blood or cerebrospinal fluid (CSF) can be used to identify nutritional factors that may contribute to faster cognitive decline in AD.

Cross-sectional studies comparing nutritional biomarker levels in AD and controls have reported lower levels of several nutrients in AD.<sup>2,3</sup> Moreover, large population-based studies have reported higher levels of homocysteine and cholesterol to be a risk factor for AD-type dementia.<sup>8,9</sup> A recent study proposed a nutritional risk index including levels of omega-3 fatty acids, vitamin D, and homocysteine that might help to identify non-demented elderly at risk for cognitive decline.<sup>6</sup> These findings suggest that nutritional biomarkers have potential to aid in the identification of targets for dietary interventions.

Further support that optimization of nutritional biomarker levels might be beneficial comes from studies of the Mediterranean diet. Higher adherence to the Mediterranean diet is associated with a reduced risk for AD and for mild cognitive impairment (MCI) conversion to AD.<sup>10–12</sup> The Mediterranean diet is rich in antioxidant nutrients that have been reported to be low in blood from AD patients.<sup>13</sup> Moreover, higher adherence to the Mediterranean diet reduces the intake of saturated fat, in comparison to the typical Western diet, and consequently lowers cholesterol levels.<sup>13,14</sup>

Memory-clinic patients are at increased risk for cognitive decline and eager to take benefit from dietary advice or interventions.<sup>15</sup> The role of nutritional biomarkers in the memory-clinic setting is, however, less clear. A previous cross-sectional study showed that lower levels of several nutritional biomarkers are already prevalent in patients with MCI.<sup>16</sup> In addition, in a retrospective study of patients with subjective cognitive decline (SCD) and MCI, we found modest associations between higher levels of high-density lipoprotein (HDL) cholesterol and lower levels of CSF S-adenosylmethionine (SAM) and clinical progression.<sup>17</sup> The role of nutritional biomarkers across the complete cognitive spectrum of AD remains, however, largely unknown. Hence, in this prospective study, we studied the association of nutritional biomarkers with clinical progression, in a memory clinic population with SCD, MCI, and AD-type dementia.

## 2 | METHODS

### 2.1 | Patients

The NUDAD (Nutrition, the Unrecognized Determinant in Alzheimer's Disease) study is a prospective cohort that aims to identify nutritional determinants in AD-type dementia and predementia stages, with 3-year clinical follow-up.<sup>4</sup> The NUDAD study is nested within the Amsterdam Dementia Cohort and includes patients who visited the Alzheimer Center Amsterdam between September 2015 and August 2017; were diagnosed with SCD, MCI, or AD; and had a Mini-Mental State Examination (MMSE) >16. We excluded 23 patients that had no nutritional biomarker measurements and one patient whose initial AD diagnosis was retracted after 3 months, leaving 528 participants for data analysis, including 204 individuals with SCD, 130 patients with MCI, and 194 patients with AD. All participants underwent standardized dementia screening, including extensive neuropsychological assessment, neurological examination, magnetic resonance imaging, lumbar puncture, and blood sampling.<sup>18</sup> Diagnoses for MCI and AD were made in multidisciplinary consensus meetings according to the National Institute on Aging-Alzheimer's Association criteria.<sup>19,20</sup> Individuals with SCD presented with memory complaints but performed normally on all clinical and cognitive examinations, that is, did not fulfill criteria for MCI, dementia, or any psychiatric diagnosis. Written informed consent was obtained from all participants and the protocol was approved by the local Medical Ethical Committee. Diabetes mellitus, hypertension, and hypercholesterolemia were defined as self-reported medication use or a medical history for these conditions at baseline. Apolipoprotein E (APOE) genotype was determined using a QIAxcel DNA Fast Analysis kit (Qiagen, Venlo, the Netherlands) after DNA isolation from 7 to 10 mL ethylenediaminetetraacetic acid (EDTA) blood. Participants were classified as  $\epsilon 4$  carrier ( $\geq 1$  allele) or non-carrier.<sup>21</sup>

### 2.2 | Follow-up

Follow-up took place by routine annual visits to our memory clinic, in which neuropsychological testing and medical examination were

**HIGHLIGHTS**

- Higher low-density lipoprotein (LDL) cholesterol levels in subjective cognitive decline (SCD) were associated with clinical progression.
- This association was driven by individuals that did not use lipid-lowering medication.
- Lower uridine levels in Alzheimer's disease (AD) were associated with clinical progression.

repeated. If participants were unable or did not want to attend annual clinical follow-up, the participant or a proxy was invited for a short telephone interview. In these telephone interviews we surveyed the following items: change of diagnosis or living situation (eg, independent, institutionalized), and self-reported change in cognitive function (stable/improving/fluctuating/decline). Mean follow-up was  $2.1 \pm 0.9$  years. Main outcome was time to clinical progression, which was considered present when at least one of the following three criteria was met: (1) a follow-up syndrome diagnosis of MCI or dementia (in SCD/MCI); an increase of  $\geq 1$  point on the global clinical dementia rating scale (CDR; in AD),<sup>22</sup> (2) deceased or admission to a nursing home, (3) subjective decline in cognitive function as reported during the telephone interviews. Time to clinical progression was defined as time between baseline visit and first report of progression.

**2.3 | Nutritional biomarker measures**

Blood and CSF samples were obtained within 1 year from baseline visit (median [range] 0 [0 to 360] days) and before first report of progression (median [range] 475 [73 to 1355] days). Blood was collected in 6 mL tubes (BD, Plymouth, United Kingdom) for EDTA plasma or serum separation. CSF was obtained by lumbar puncture using a 25-gauge needle, and collected in 10 mL polypropylene tubes (Sarstedt, Nümbrecht, Germany). Within 2 hours, blood and CSF was centrifuged at  $1800 \times g$  for 10 minutes at room temperature, aliquoted in portions of 0.5 mL, and stored at  $-80^{\circ}\text{C}$  until further analysis. In total 13 nutritional biomarkers were measured in serum or plasma (range  $n = 451$  to  $516$ , 85% to 98%), except for SAM and S-adenosylhomocysteine (SAH), which were measured in CSF ( $n = 284$  to  $285$ , 54%).<sup>17</sup> The number of samples that could be measured for each nutritional biomarker depended on the available sample volume. Nutritional biomarker concentrations were considered regardless of fasted ( $n = 73$ ) or non-fasted state ( $n = 405$  serum;  $n = 399$  plasma). Most analyses were performed at the Amsterdam UMC (Amsterdam, the Netherlands). The uridine measurements were performed at Maastricht UMC+ (Maastricht, the Netherlands). Detailed information on measurement methods of the nutritional biomarkers can be found in Text S1 in supporting information.

**RESEARCH IN CONTEXT**

1. Systematic review: Impaired nutritional status has been associated with faster cognitive decline in community-based populations. Few studies have investigated whether nutritional biomarker levels in blood and cerebrospinal fluid can be used to identify nutritional factors associated with clinical progression in patients with subjective cognitive decline, mild cognitive impairment or Alzheimer's disease (AD)-type dementia.
2. Interpretation: Higher low-density lipoprotein (LDL) cholesterol levels in subjective cognitive decline (SCD) and lower uridine levels in AD were associated with clinical progression. The association for higher LDL cholesterol levels in SCD was driven by individuals that did not use lipid-lowering medication. Additionally, in a combined analysis of predementia stages in our prospective and retrospective cohort, higher high-density lipoprotein (HDL) cholesterol levels and lower cerebrospinal fluid (CSF) S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) levels in mild cognitive impairment (MCI) with clinical progression.
3. Future directions: Our findings suggest that further studies should investigate if dietary interventions that influence cholesterol and uridine metabolism can slow the rate of clinical progression in memory-clinic patients.

**2.4 | Amyloid status**

Amyloid status as assessed by either positron tomography (PET) and/or CSF analysis was available within 1 year of baseline visit in 423/528 participants (PET  $n = 51$ ; CSF  $n = 234$ ; PET and CSF  $n = 138$ ). Patients were classified as having a positive amyloid status as at least one of the modalities (ie, CSF or PET) revealed amyloid positivity. Amyloid positivity on amyloid PET scans was evaluated by an experienced nuclear medicine physician.<sup>23</sup> Amyloid beta peptide  $_{1-42}$  ( $A\beta_{42}$ ) were measured in CSF on a routine basis using commercially available enzyme-linked immunosorbent assays (Innotest  $\beta$ -amyloid $_{(1-42)}$ , Ghent, Belgium) as previously described.<sup>24</sup> For  $A\beta_{42}$ , we used a drift corrected cut-off  $< 813$  pg/mL for amyloid positivity.<sup>25</sup>

**2.5 | Statistical analysis**

Nutritional biomarkers were log-transformed when not normally distributed and subsequently converted to z-scores to enable comparison of effect sizes. Descriptive characteristics and nutritional biomarkers were compared on their outcome (clinical progression yes/no) in the total group and stratified for baseline syndrome diagnosis (SCD/MCI/AD) using  $\chi^2$  tests, Mann-Whitney  $U$  tests, and  $t$ -tests when

**TABLE 1** Baseline characteristics of the Nutrition, the Unrecognized Determinant in Alzheimer's Disease (NUDAD) study population

Baseline diagnosis	All		SCD		MCI		AD	
	No progression	Progression	No progression	Progression	No progression	Progression	No progression	Progression
	361	167	182	22	85	45	94	100
Age, years	63.65 ± 8.13	66.26 ± 8.39*	60.42 ± 7.45	62.61 ± 8.38	65.74 ± 7.34	66.85 ± 8.16	68.02 ± 7.44	66.79 ± 8.37
Female	166 (46)	78 (47)	86 (47)	9 (41)	34 (40)	19 (42)	46 (49)	50 (50)
Education (Verhage scale)	5 (5, 6)	5 (4, 6)	6 (5, 6)	6 (5, 6)	5 (5, 6)	5 (4, 6)	5 (5, 6)	5 (4, 6)
MMSE	27 (25, 29)	24 (21, 27)*	29 (27, 29)	29 (27, 29)	27 (25, 28)	26 (25, 28)	24 (22, 26)	22 (20, 24)*
APOE ε4 carrier <sup>a</sup>	173 (51)	102 (63)*	70 (41)	13 (62)	46 (56)	25 (60)	57 (66)	64 (65)
Follow-up duration, years	2.17 ± 0.90	2.11 ± 0.82	2.18 ± 0.93	2.23 ± 0.79	2.28 ± 0.69	2.09 ± 0.90	2.04 ± 0.99	2.09 ± 0.79
BMI, kg/m <sup>2</sup>	26.24 ± 4.22	24.97 ± 3.86*	27.04 ± 4.72	25.79 ± 4.25	25.65 ± 3.72	24.99 ± 3.50	25.23 ± 3.24	24.77 ± 3.93
Smoker								
Current	51 (14)	25 (15)	25 (14)	2 (9)	15 (18)	8 (18)	11 (12)	15 (15)
Former	141 (39)	62 (37)	69 (38)	13 (59)	31 (36)	17 (38)	41 (44)	32 (32)
No	169 (47)	80 (48)	88 (48)	7 (32)	39 (46)	20 (44)	42 (45)	53 (53)
Alcohol, glasses per day	0.5 (0.0, 2.0)	0.5 (0.0, 2.0)	0.5 (0.0, 1.4)	0.8 (0.0, 2.0)	0.5 (0.0, 2.0)	0.5 (0.0, 1.0)	0.5 (0.0, 1.9)	0.5 (0.0, 1.6)
Diabetes mellitus	35 (10)	13 (8)	11 (6)	3 (14)	15 (18)	2 (4)	9 (10)	8 (8)
Hypertension	131 (36)	51 (31)	64 (35)	6 (27)	33 (39)	16 (36)	34 (36)	29 (29)
Hypercholesterolemia	109 (30)	42 (25)	43 (24)	4 (18)	30 (35)	15 (33)	36 (38)	23 (23)*
Lipid-lowering medication	98 (27)	35 (22)	39 (21)	2 (9)	25 (29)	13 (29)	34 (36)	21 (21)*
Amyloid positive <sup>b</sup>	143 (49)	110 (83)*	34 (24)	10 (69)*	37 (53)	26 (65)	72 (92)	73 (95)

Abbreviations: AD, Alzheimer's disease; APOE, apolipoprotein E; BMI, body mass index; CSF, cerebrospinal fluid; IQR, interquartile range; MCI, mild cognitive impairment; PET, positron emission tomography; SCD, subjective cognitive decline; SD, standard deviation.

Notes: Data in mean ± SD, n(%), median (IQR), groups were compared on their outcome (stable vs progression) in the total cohort and within subgroups of their baseline syndrome diagnosis (SCD/MCI/AD). Education was rated using Verhage's scale ranging from 1 (low) to 7 (high).<sup>52</sup> \**P* <.05 values correspond to *t*-test,  $\chi^2$  test or Mann-Whitney *U* tests when appropriate.

<sup>a</sup>APOE genotype was available in 500 participants (95%).

<sup>b</sup>Amyloid status (CSF or PET) was available in 423 (80%) participants.

appropriate. Cox proportional hazard models were used to investigate if baseline nutritional biomarkers (continuous determinants) were associated with time to clinical progression (outcome) in the total group. We present an unadjusted model (model 1) and a model adjusted for sex, age, diagnosis, and lipid-lowering medication (model 2). Hazard ratios (HR) are presented with 95% confidence intervals (CI). Subsequently, we repeated the models (1) stratified for baseline diagnosis, (2) in amyloid-positive patients only, and (3) stratified for lipid-lowering medication (yes/no). Last, we focused our analysis on predementia stages, combining individual patient data from the current cohort and from the previously published, retrospective cohort.<sup>17</sup> Eight patients were included in both cohorts, and were therefore excluded from the retrospective cohort. For this analysis, we included only patients with SCD or MCI and we restricted the definition of clinical progression in both cohorts to clinical progression to MCI or dementia (to ensure uniformity over cohorts). The retrospective cohort included 142 patients with SCD (age 61 ± 10 years, F 43%) and 149 patients with MCI (age 66 ± 8 years, F 38%); mean follow-up was 3.4 ± 2.2 years. We used Cox proportional hazard models in two models: a model only adjusted for cohort (model 1) and a model adjusted for cohort, sex, age, diagnosis, and lipid-lowering medication (model 2). To

assess if associations differed per cohort, we added interaction terms to the model (nutritional biomarkers x cohort). If there was an interaction between cohort and nutritional biomarker (*P* <.10), results are additionally reported for the two cohorts separately. Analyses were performed in R version 3.6.1. Results are reported at the threshold of *P* <.05.

### 3 | RESULTS

#### 3.1 | Prospective cohort

Clinical progression was observed in 22 (11%) patients with SCD, 45 (35%) patients with MCI, and 100 (52%) patients with AD. Patients who showed clinical progression were older, had lower MMSE scores and body mass index (BMI), were more often APOE ε4 carriers, and were more often amyloid positive than patients without clinical progression (Table 1).

In the total cohort, patients with clinical progression had higher homocysteine levels than patients without clinical progression (Table 2). Cox proportional hazard models similarly showed that higher

**TABLE 2** Nutritional biomarker levels according to baseline diagnosis and clinical progression

Baseline diagnosis	N		All		N		SCD		N		MCI		N		AD		
	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	
Progression (-/+)																	
Serum HDL, mmol/L	318	1.33 ± 0.41	145	1.33 ± 0.39	161	1.28 ± 0.40	22	1.30 ± 0.39	71	1.35 ± 0.42	41	1.32 ± 0.42	86	1.42 ± 0.43	82	1.34 ± 0.38	
Serum LDL, mmol/L	318	2.41 ± 0.82	145	2.62 ± 0.93	161	2.33 ± 0.83	22	2.85 ± 0.90*	71	2.45 ± 0.85	41	2.39 ± 0.77	86	2.54 ± 0.78	82	2.67 ± 0.99	
Serum total cholesterol, mmol/L	318	4.39 ± 1.04	145	4.59 ± 1.16	161	4.28 ± 1.08	22	4.85 ± 1.24	71	4.41 ± 1.10	41	4.24 ± 0.94	86	4.59 ± 0.92	82	4.69 ± 1.21	
Serum triglycerides, mmol/L	318	1.46 ± 0.95	145	1.43 ± 0.75	161	1.53 ± 1.06	22	1.55 ± 0.75	71	1.38 ± 0.76	41	1.18 ± 0.51	86	1.38 ± 0.87	82	1.52 ± 0.82	
Plasma glucose, nmol/L	350	7.08 ± 1.91	164	7.16 ± 2.02	176	6.92 ± 1.75	21	7.07 ± 2.07	84	7.25 ± 2.16	44	7.15 ± 2.34	90	7.24 ± 1.95	99	7.18 ± 1.87	
Plasma homocysteine, μmol/L	314	12.33 ± 3.63	143	13.16 ± 3.75*	158	11.58 ± 3.27	22	11.65 ± 2.26	70	12.99 ± 3.50	41	13.23 ± 3.39	86	13.20 ± 4.09	80	13.54 ± 4.16	
Serum folate, nmol/L	352	19.03 ± 9.77	164	17.90 ± 8.86	178	19.83 ± 11.06	21	16.76 ± 6.30	84	18.45 ± 8.43	44	17.61 ± 8.57	90	18.00 ± 8.01	99	18.26 ± 9.48	
Serum vitamin B12, pmol/L	351	372 ± 398	164	333 ± 224	177	364 ± 382	21	305 ± 187	84	359 ± 306	44	325 ± 151	90	398 ± 496	99	342 ± 258	
CSF SAM, nmol/L	198	169 ± 37	86	164 ± 39	91	166 ± 34	13	169 ± 44	48	176 ± 48	24	156 ± 46	59	166 ± 32	49	167 ± 33	
CSF SAH, nmol/L	198	15.79 ± 5.01	87	16.56 ± 6.27	91	14.96 ± 4.84	13	18.56 ± 9.83	48	16.75 ± 4.87	25	15.72 ± 5.64	59	16.30 ± 5.25	49	16.46 ± 5.37	
Plasma vitamin A, μmol/L	314	2.18 ± 0.52	143	2.11 ± 0.47	158	2.19 ± 0.49	22	2.05 ± 0.44	70	2.17 ± 0.52	41	2.03 ± 0.43	86	2.18 ± 0.58	80	2.16 ± 0.50	
Plasma vitamin E, μmol/L	314	35.66 ± 8.27	143	35.53 ± 7.92	158	35.02 ± 8.42	22	36.14 ± 6.66	70	35.61 ± 8.68	41	34.27 ± 7.75	86	36.87 ± 7.56	80	36.02 ± 8.33	
Plasma uridine, nmol/L	308	4216 ± 1348	143	3957 ± 1176	156	4146 ± 1291	22	4290 ± 1449	67	4404 ± 1632	41	4386 ± 1163	85	4196 ± 1197	80	3646 ± 1009*	

Abbreviations: AD, Alzheimer's disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MCI, mild cognitive impairment; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; SCD, subjective cognitive decline.

Notes: Data in mean ± SD, groups were compared on their outcome (stable vs progression) in the total cohort and within subgroups of their baseline syndrome diagnosis (SCD/MCI/AD).

\*P < .05 values correspond to t-tests on log-transformed nutritional biomarker levels

homocysteine levels were associated with a higher risk of clinical progression (HR [95% CI] 1.20 [1.02 to 1.41]), but this association was lost after adjustment for covariates (Table 3).

Stratified for baseline clinical diagnosis, we found that in SCD, higher levels of low-density lipoprotein (LDL) cholesterol were associated with clinical progression (HR [95% CI] 1.88 [1.04 to 3.41], model 2; Table 3). In AD, lower uridine levels were associated with clinical progression (HR [95% CI] 0.79 [0.63 to 0.99], model 2). No significant associations with clinical progression were observed in the MCI group. An exploratory analysis additionally adjusting for APOE  $\epsilon$ 4 genotype and having  $\geq 1$  risk factor for cardiovascular disease (ie, former or current smoking, hypertension, hypercholesterolemia, diabetes mellitus) showed comparable associations between higher LDL cholesterol levels and clinical progression in SCD (HR [95% CI] 1.63 [0.88 to 3.02]) and between lower uridine levels and clinical progression in AD (HR [95% CI] 0.78 [0.62 to 0.99]; Table S1 in supporting information).

To evaluate whether the observed associations between nutritional markers and clinical progression were present in the Alzheimer's pathologic spectrum we repeated the models in the subgroup of 253 patients with positive amyloid status (age  $66 \pm 8$ , 130 [51%] females [F], 45 SCD, 63 MCI, 145 AD, 110 [43%] clinical progression). Effect sizes remained comparable for homocysteine in the total cohort (HR [95% CI] 1.08 [0.89 to 1.31], model 1), LDL cholesterol in SCD (HR [95% CI] 2.46 [0.89 to 6.81], model 2), and uridine in AD (HR [95% CI] 0.82 [0.63 to 1.07], model 2), although significance was lost probably due to lower power (Table 2).

Finally, we reanalyzed the associations between cholesterol levels and clinical progression stratified for lipid-lowering medication (yes,  $n = 115$ ; no,  $n = 348$ ). Lower total cholesterol and LDL cholesterol levels were associated with clinical progression in medication users (HR [95% CI] 0.57 [0.40 to 0.81], 0.83 [0.70 to 0.97], model 2), while higher levels of total cholesterol and LDL cholesterol were associated with clinical progression in patients who did not use lipid-lowering medication (HR [95% CI] 1.15 [0.91 to 1.44], 1.18 [0.90 to 1.54], model 2; Table 3). These associations were largely similar across diagnostic groups, but strongest for SCD patients who did not use lipid-lowering medication (HR [95% CI] 2.11 [1.10 to 4.06], 1.73 [1.04 to 2.86], model 2).

### 3.2 | Analysis of predementia stages across two cohorts

In an additional analysis, we focused our analysis on predementia stages (ie, SCD and MCI) combining individual patient data from the retrospective cohort and prospective cohort. Clinical progression was observed in 37 (11%) patients with SCD and 71 (25%) patients with MCI. Higher homocysteine levels were associated with clinical progression in model 1 (HR [95% CI] 1.21 [1.01 to 1.47]), but this association was lost in model 2 (Table 4). Higher HDL cholesterol levels were associated with clinical progression (HR [95% CI] 1.31 [1.04 to 1.64], model 2). Interactions between cohort and nutritional biomarkers were only found for LDL cholesterol (HR [95% CI] retrospective cohort: 0.97 [0.75 to 1.25]; prospective cohort: 1.52 [0.91 to 2.55], model 2).

Stratified for syndrome diagnosis, higher HDL cholesterol levels were associated with clinical progression in SCD (HR [95% CI] 1.48 [1.02 to 2.15], model 2), while lower CSF SAM and SAH levels were associated with clinical progression in MCI (HR [95% CI] 0.72 [0.58 to 0.90], 0.74 [0.54 to 1.00], model 2; Table 4).

## 4 | DISCUSSION

The main finding of this memory-clinic cohort study is that higher LDL cholesterol levels in SCD and lower uridine levels in AD were associated with clinical progression. The association for higher LDL cholesterol levels in SCD was driven by individuals that did not use lipid-lowering medication. Our findings extend previous work in population-based studies by showing associations of nutritional biomarkers with clinical progression in a memory-clinic sample.<sup>8,9</sup>

In our prospective study, we found that higher LDL cholesterol levels were associated with clinical progression in SCD. This association was driven by SCD patients who did not use lipid-lowering medication. Mid-life hypercholesterolemia is often reported as a risk factor for cognitive decline and dementia.<sup>8,26,27</sup> This association is less clear in late life and in the symptomatic phase of AD.<sup>28-31</sup> This might explain why the association between higher LDL cholesterol and clinical progression is restricted to SCD and not found in MCI or AD. Our findings indicate that the relation between cholesterol and clinical progression is complex and seemingly dependent on disease stage and medication use.

The finding that lower levels of uridine were associated with clinical progression in patients with AD extends on previous cross-sectional studies that described lower levels of CSF and plasma uridine in MCI and AD in comparison to controls.<sup>16,32,33</sup> Uridine is a precursor for phospholipids and is required for neuronal cell membrane formation. Higher uridine levels may have a positive effect on synaptic function and synapse membrane formation, which might alleviate synaptic dysfunction in AD.<sup>34-36</sup> The association of lower levels of uridine in AD might be explained by a lower nutrient intake or an increased need for uridine to regenerate synaptic membranes in AD.<sup>34,37</sup> Future studies that assess more nutritional biomarkers involved in the phospholipid metabolism, such as choline and docosahexaenoic acid, will help to gain more insight in the role of the phospholipid metabolism in the clinical progression of AD. Because our findings for uridine were restricted to the AD dementia stage the associations of lower uridine levels with increased risk of clinical progression might only develop in relation to homeostatic changes during the late symptomatic phase.

Additionally, in a combined analysis of predementia stages in our prospective and retrospective cohort, higher HDL cholesterol levels and lower CSF SAM and SAH levels in MCI were associated with clinical progression. The role of HDL cholesterol levels in AD is inconclusive.<sup>17,38</sup> One explanation for our findings could be that HDL is dysfunctional in AD, as also reported for type 2 diabetes and coronary heart disease, resulting in impaired protective effects while HDL cholesterol levels remain normal.<sup>39</sup> Our findings for higher homocysteine levels (prospective cohort and combined analysis) and lower CSF SAM and SAH levels in MCI (combined analysis) are in line with

**TABLE 3** Cox proportional hazard models for the association of nutritional biomarkers with clinical progression during follow-up

Baseline diagnosis	All						SCD			MCI			AD		
	N	Model 1		Model 2		N	Model 1		Model 2		N	Model 1		Model 2	
		Model 1	Model 2	Model 1	Model 2		Model 1	Model 2	Model 1	Model 2		Model 1	Model 2		
HDL	463	1.01 (0.86–1.19)	0.93 (0.77–1.11)	183	1.07 (0.71–1.62)	1.04 (0.66–1.65)	112	0.93 (0.69–1.26)	0.84 (0.59–1.19)	168	0.9 (0.72–1.12)	0.9 (0.7–1.15)			
LDL	463	1.11 (0.92–1.34)	0.94 (0.78–1.12)	183	2.01 (1.15–3.5)*	1.88 (1.04–3.41)*	112	0.93 (0.77–1.11)	0.91 (0.76–1.09)	168	0.93 (0.7–1.23)	0.8 (0.58–1.09)			
Total cholesterol	463	1.12 (0.94–1.32)	0.95 (0.78–1.15)	183	1.64 (1.05–2.55)*	1.57 (0.99–2.51)	112	0.85 (0.63–1.15)	0.79 (0.57–1.09)	168	0.95 (0.74–1.22)	0.86 (0.65–1.14)			
Triglycerides	463	0.99 (0.84–1.17)	1.02 (0.86–1.21)	183	1.11 (0.75–1.64)	1.2 (0.79–1.83)	112	0.81 (0.59–1.12)	0.83 (0.59–1.16)	168	1.12 (0.89–1.41)	1.12 (0.89–1.41)			
Glucose	514	1.03 (0.88–1.19)	0.97 (0.83–1.13)	197	1.08 (0.69–1.71)	1.21 (0.74–1.97)	128	0.98 (0.75–1.28)	0.97 (0.74–1.27)	189	0.9 (0.74–1.1)	0.95 (0.77–1.16)			
Homocysteine	457	1.2 (1.02–1.41)*	1.09 (0.92–1.29)	180	1.03 (0.64–1.64)	1.02 (0.61–1.68)	111	1.09 (0.78–1.53)	1.13 (0.79–1.6)	166	1.07 (0.88–1.3)	1.08 (0.87–1.33)			
Folate	516	0.9 (0.77–1.05)	0.93 (0.79–1.08)	199	0.77 (0.49–1.2)	0.67 (0.41–1.09)	128	0.94 (0.7–1.27)	0.9 (0.66–1.23)	189	0.99 (0.82–1.2)	0.98 (0.81–1.2)			
Vitamin B12	515	0.97 (0.83–1.14)	0.93 (0.79–1.1)	198	0.84 (0.52–1.38)	0.82 (0.49–1.38)	128	0.96 (0.7–1.3)	0.91 (0.66–1.26)	189	0.95 (0.77–1.18)	0.96 (0.77–1.19)			
CSF SAM	284	0.92 (0.75–1.13)	0.9 (0.73–1.12)	104	0.99 (0.59–1.65)	1.12 (0.65–1.93)	72	0.76 (0.55–1.05)	0.73 (0.52–1.02)	108	0.98 (0.69–1.39)	1 (0.69–1.43)			
CSF SAH	285	1.13 (0.91–1.40)	1.01 (0.79–1.29)	104	1.48 (0.93–2.34)	1.34 (0.79–2.26)	73	0.83 (0.52–1.31)	0.66 (0.36–1.2)	108	0.96 (0.7–1.31)	0.98 (0.7–1.38)			
Vitamin A	457	0.93 (0.80–1.09)	0.96 (0.81–1.13)	180	0.82 (0.56–1.19)	0.81 (0.54–1.22)	111	0.83 (0.62–1.12)	0.85 (0.62–1.15)	166	1.08 (0.88–1.33)	1.11 (0.89–1.39)			
Vitamin E	457	0.98 (0.83–1.16)	0.85 (0.7–1.02)	180	1.23 (0.8–1.91)	1.18 (0.75–1.87)	111	0.89 (0.67–1.19)	0.79 (0.56–1.11)	166	0.86 (0.69–1.08)	0.79 (0.61–1.02)			
Uridine	451	0.88 (0.75–1.03)	0.9 (0.76–1.06)	178	1.04 (0.69–1.58)	0.98 (0.65–1.49)	108	1 (0.75–1.35)	0.98 (0.72–1.33)	165	0.79 (0.63–0.99)*	0.79 (0.63–0.99)*			

Abbreviations: AD, Alzheimer's disease; CSF, cerebrospinal fluid; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; MCI, mild cognitive impairment; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; SCD, subjective cognitive decline.

Notes: Cox proportional hazard model 1 unadjusted, model 2 adjusted for age, sex and lipid-lowering medication and in total group also for diagnosis. Data are presented as hazard ratio (95% confidence interval). Nutritional markers were log-transformed and converted to z-scores prior to analysis.

\*  $P < 0.05$

**TABLE 4** Cox proportional hazard models for the association of nutritional biomarkers with clinical progression in predementia stages in two independent cohorts restricting the definition of clinical progression to progression to mild cognitive impairment (MCI) or dementia

Baseline diagnosis	N	All		N	SCD		N	MCI	
		Model 1	Model 2		Model 1	Model 2		Model 1	Model 2
HDL	586	1.24 (1.03–1.49)*	1.31 (1.04–1.64)*	325	1.14 (0.84–1.54)	1.48 (1.02–2.15)*	261	1.38 (1.09–1.76)*	1.23 (0.92–1.66)
LDL	586	1.06 (0.87–1.28)	1.08 (0.88–1.33)	325	1.13 (0.8–1.62)	1.11 (0.75–1.64)	261	1.08 (0.86–1.36)	1.03 (0.81–1.3)
Total cholesterol	586	1.07 (0.88–1.3)	1.1 (0.88–1.36)	325	1.2 (0.85–1.68)	1.23 (0.85–1.79)	261	1.07 (0.84–1.37)	0.96 (0.74–1.26)
Triglycerides	586	0.87 (0.72–1.05)	0.86 (0.7–1.06)	325	1.04 (0.76–1.42)	0.87 (0.61–1.24)	261	0.76 (0.59–0.97)*	0.79 (0.61–1.02)
Glucose	517	1.21 (0.99–1.49)	1.19 (0.96–1.47)	296	1.31 (0.92–1.87)	1.22 (0.82–1.82)	221	1.12 (0.87–1.43)	1.13 (0.89–1.45)
Homocysteine	568	1.21 (1.01–1.47)*	1.05 (0.84–1.3)	311	1.14 (0.82–1.58)	0.87 (0.59–1.28)	257	1.11 (0.87–1.43)	1.25 (0.96–1.62)
Folate	618	0.99 (0.81–1.2)	1 (0.83–1.21)	341	1.2 (0.84–1.74)	1.2 (0.83–1.74)	277	0.94 (0.76–1.16)	0.91 (0.73–1.14)
Vitamin B12	544	1.02 (0.83–1.27)	1.02 (0.82–1.25)	296	1.18 (0.82–1.68)	1.05 (0.72–1.53)	248	0.95 (0.73–1.25)	0.93 (0.7–1.22)
CSF SAM	466	0.86 (0.7–1.04)	0.86 (0.71–1.04)	245	1.11 (0.77–1.62)	1.23 (0.85–1.79)	221	0.76 (0.61–0.94)	0.72 (0.58–0.9)*
CSF SAH	468	1.06 (0.87–1.29)	0.87 (0.7–1.09)	246	1.31 (0.95–1.79)	1.01 (0.72–1.42)	222	0.77 (0.57–1.03)	0.74 (0.54–1)*
Vitamin A	582	1.03 (0.86–1.24)	1.05 (0.85–1.28)	322	1.1 (0.79–1.52)	1.07 (0.76–1.51)	260	0.94 (0.75–1.18)	1.07 (0.83–1.39)
Vitamin E	582	1.04 (0.86–1.27)	1.07 (0.87–1.31)	322	1.11 (0.79–1.56)	1.1 (0.77–1.56)	260	1.09 (0.86–1.38)	0.99 (0.77–1.28)
Uridine	571	1.03 (0.86–1.24)	0.99 (0.83–1.2)	316	1.05 (0.77–1.42)	1.09 (0.8–1.48)	255	0.94 (0.74–1.19)	0.91 (0.72–1.15)

Abbreviations: AD, Alzheimer's disease; CSF, cerebrospinal fluid; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; MCI, mild cognitive impairment; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; SCD, subjective cognitive decline.

Notes: Cox proportional hazard model 1 adjusted for cohort, model 2 adjusted for cohort, age, sex and lipid-lowering medication and in total group also for diagnosis. Data are presented as hazard ratio (95% confidence interval). Nutritional markers were log-transformed and converted to z-scores prior to analysis.

\* $P < .05$

previous reports of low CSF SAM levels in AD versus controls,<sup>40,41</sup> and with higher homocysteine levels as a risk factor for dementia.<sup>9</sup> Hyperhomocysteinemia is one of the most widely studied nutritional risk factors in AD and can be caused by suboptimal levels of folate, vitamin B12, and vitamin B6.<sup>42</sup> Elevated homocysteine levels are associated with an increased risk of atherosclerosis and stroke, which can contribute to cognitive decline.<sup>43,44</sup> Homocysteine is a metabolite in the one-carbon metabolism in which SAM is the direct methyl group donor.<sup>45</sup> SAM together with SAH affects the methylation of DNA, RNA, neurotransmitters, and phospholipids and therefore, might be biologically influencing the AD disease process.<sup>46</sup> For example, low levels of SAM have been suggested to influence expression of presenilin 1 and  $\beta$ -secretase and increase  $A\beta$  production.<sup>47,48</sup> SAM and SAH levels in AD have mostly been investigated in brain tissue or CSF.<sup>40,49</sup> Measurements in plasma are less invasive but require deproteinized blood samples that were unavailable in this study.<sup>50</sup> Future studies should examine SAM/SAH changes in deproteinized plasma as this will enhance the implementation of these markers in large population-based studies that usually do not collect CSF.

The current prospective study was set up to extend on the findings from our previous retrospective cohort study.<sup>17</sup> Our previous findings for higher HDL cholesterol and lower CSF SAM levels and clinical progression remained in our combined analyses, but could not be replicated in the prospective cohort alone. In our previous report on the retrospective cohort we additionally applied an integrative approach to study the associations between combinations of nutritional biomarkers to clinical progression. Because we measured only a subset of the nutritional biomarkers in the current prospective

cohort, we could not validate the previously identified profiles, and we show associations for single biomarkers. Overall, the heterogeneous findings in the two cohorts stress that associations between nutritional biomarkers and clinical progression are highly complex. For both cohorts, patients were included from our tertiary memory clinic and thus received similar clinical work-up. In the retrospective cohort, however, we oversampled patients with clinical progression to increase statistical power, which could perhaps explain the difference in findings between the two cohorts. Another explanation could be that other factors, such as medication use, cause this variability.

Strengths of this study are that our participants underwent standardized cognitive screening and follow-up, had CSF or PET amyloid status available, and were measured for several nutritional biomarkers. Furthermore, this study extended our previous retrospective cohort, as we investigated the 13 nutritional biomarkers that showed most promising associations with clinical progression in retrospective cohort. This study also has some limitations. We defined deceased, nursing home admission, and subjective progression of cognitive symptoms as clinical events in our outcome measure. One could argue that these events might not always be a consequence of neurodegenerative disease progression. This enabled us, however, to capture detrimental outcomes in a wider context than measured at the clinical visits to our memory clinic. Furthermore, we used both fasting and non-fasting samples; however, we found no statistical evidence for effect modification or confounding by fasting status (data not shown).

In conclusion, we found associations between higher LDL cholesterol levels in SCD and lower uridine in AD with clinical progression. Our findings are biologically plausible and fit with previous findings



in animal studies and cell studies of disturbed uridine and cholesterol metabolism in AD.<sup>34,51</sup> Our findings suggest that further studies should investigate if dietary interventions that influence cholesterol and uridine metabolism can slow the rate of clinical progression in memory-clinic patients.

## ACKNOWLEDGMENTS

The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Research by the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. W.F. is recipient of a donation by stichting Equilibrio, and of a ZonMW Memorabel grant (#733050814). F.L., A.D., M.K., H.H. are appointed on the NUDAD project, which is funded by NWO-FCB (project number 057-14-004). W.F. holds the Pasman chair. We acknowledge members of the NUDAD project team: Amsterdam University Medical Center location VUmc: Wiesje van der Flier, Maartje Kester, Philip Scheltens, Charlotte Teunissen, Marian de van der Schueren, Francien de Leeuw, Astrid Doorduijn, Jay Fieldhouse, Heleen Hendriksen, José Overbeek, Els Dekkers; Vrije Universiteit Amsterdam: Marjolein Visser; Wageningen University & Research: Ondine van de Rest, Sanne Boesveldt; DSM: Peter van Dael, Manfred Eggersdorfer; Nutricia Research: John Sijben, Nick van Wijk, Amos Attali, Martin Verkuil; FrieslandCampina: Rolf Bos, Cecile Singh-Povel, Ellen van den Heuvel, Martijn Veltkamp.

## FUNDING INFORMATION

The NUDAD project is funded by NWO-FCB (project number 057-14-004) and Francisca A. de Leeuw, Astrid S. Doorduijn, Maartje I. Kester, Heleen M.A. Hendriksen are appointed on this project.

## CONFLICTS OF INTEREST

Francisca A. de Leeuw, Betty M. Tijms, Astrid S. Doorduijn, Heleen M. A. Hendriksen, Ondine van de Rest, Marian A. E. de van der Schueren, Marjolein Visser, Jorgen Bierau, and Maartje I. Kester report no disclosures. Ellen G. H. M. Heuvel is an employee of FrieslandCampina. Nick van Wijk is an employee of Danone Nutricia Research. Bart N. van Berckel received research support from ZonMW, AVID radiopharmaceuticals, CTMM, and Janssen Pharmaceuticals. He is a trainer for Piramal and GE. He receives no personal honoraria. Philip Scheltens has received consultancy/speaker fees (paid to the institution) from Novartis, Vivoryon, Genentech, and EIP Pharma. C. E. Teunissen has a collaboration contract with ADx Neurosciences, performed contract research or received grants from Probiodrug, Biogen, Esai, Toyama, Janssen prevention center, Boehringer, AxonNeurosciences, Fujirebio, EIP farma, PeopleBio, and Roche. Research programs of Wiesje M. van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences and Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Janssen Stellar, Combinostics. Wiesje M. van der Flier has performed contract research for Biogen MA Inc and Boehringer Ingelheim. Wiesje

M. van der Flier has been an invited speaker at Boehringer Ingelheim and Biogen MA Inc. All funding is paid to her institution.

## REFERENCES

1. Johnson D, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. *Arch Neurol*. 2006;63:1312-1317.
2. Lopes da Silva S, Vellas B, Elemans S, et al. Plasma nutrient status of patients with Alzheimer's disease: systematic review and meta-analysis. *Alzheimers Dement*. 2014;10(4):485-502.
3. de Wilde MC, Vellas B, Girault E, Yavuz AC, Sijben JW. Lower brain and blood nutrient status in Alzheimer's disease: Results from meta-analyses. *Alzheimers Dement (N Y)*. 2017;3(3):416-431.
4. Doorduijn AS, Visser M, van de Rest O, et al. Associations of AD biomarkers and cognitive performance with nutritional status: the NUDAD project. *Nutrients*. 2019;11(5):1161.
5. Soto ME, Secher M, Gillette-Guyonnet S, et al. Weight loss and rapid cognitive decline in community-dwelling patients with Alzheimer's disease. *J Alzheimers Dis*. 2012;28(3):647-654.
6. Bowman GL, Dodge HH, Guyonnet S, et al. A blood-based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial. *Alzheimers Dement (N Y)*. 2019;5:953-963.
7. Guerin O, Soto ME, Brocker P, et al. Nutritional status assessment during Alzheimer's disease: results after one year (the REAL French Study Group). *J Nutr Health Aging*. 2005;9(2):81-84.
8. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. *Dement Geriatr Cogn Disord*. 2009;28(1):75-80.
9. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med*. 2002;346(7):476-483.
10. Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean diet, cognitive function, and dementia: a systematic review. *Epidemiology*. 2013;24(4):479-489.
11. van de Rest O, Berendsen AA, Haveman-Nies A, de Groot LC. Dietary patterns, cognitive decline, and dementia: a systematic review. *Adv Nutr*. 2015;6(2):154-168.
12. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. *Arch Neurol*. 2009;66(2):216-225.
13. Tosti V, Bertozzi B, Fontana L. Health benefits of the mediterranean diet: metabolic and molecular mechanisms. *J Gerontol A Biol Sci Med Sci*. 2018;73(3):318-326.
14. Li Y, Hruby A, Bernstein AM, et al. Saturated fats compared with unsaturated fats and sources of carbohydrates in relation to risk of coronary heart disease: a Prospective Cohort Study. *J Am Coll Cardiol*. 2015;66(14):1538-1548.
15. Wesselman LMP, Schild AK, Coll-Padros N, et al. Wishes and preferences for an online lifestyle program for brain health-A mixed methods study. *Alzheimers Dement (N Y)*. 2018;4:141-149.
16. van Wijk N, Slot RER, Duits FH, et al. Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. *Alzheimers Dement (Amst)*. 2017;8:139-146.
17. de Leeuw FA, van der Flier WM, Tijms BM, et al. Specific nutritional biomarker profiles in mild cognitive impairment and subjective cognitive decline are associated with clinical progression: the NUDAD project. *J Am Med Dir Assoc*. 2020;21(10):1513.e.1-1513.e17.
18. van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. *J Alzheimers Dis*. 2018;62(3):1091-1111.
19. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on

- diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):263-269.
20. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):270-279.
  21. van Harten AC, Jongbloed W, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. CSF ApoE predicts clinical progression in nondemented APOEepsilon4 carriers. *Neurobiol Aging*. 2017;57:186-194.
  22. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993;43(11):2412-2414.
  23. de Wilde A, van Maurik IS, Kunneman M, et al. Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. *Alzheimers Dement (Amst)*. 2017;6:143-151.
  24. Jongbloed W, Kester MI, van der Flier WM, et al. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. *Alzheimers Dement*. 2013;9(3):276-283.
  25. Tijms BM, Willems EAJ, Zwan MD, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-beta 1-42 analysis results. *Clin Chem*. 2018;64(3):576-585.
  26. Power MC, Rawlings A, Sharrett AR, et al. Association of midlife lipids with 20-year cognitive change: a cohort study. *Alzheimers Dement*. 2018;14(2):167-177.
  27. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology*. 2005;64(2):277-281.
  28. Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. *Neurology*. 2005;64(10):1689-1695.
  29. Anstey KJ, Ashby-Mitchell K, Peters R. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. *J Alzheimers Dis*. 2017;56(1):215-228.
  30. Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of mci, and rates of progression to dementia. *Neurology*. 2004;63(10):1882-1891.
  31. Ramdane S, Daoudi-Gueddah D. Mild hypercholesterolemia, normal plasma triglycerides, and normal glucose levels across dementia staging in Alzheimer's disease: a clinical setting-based retrospective study. *Am J Alzheimers Dis Other Demen*. 2011;26(5):399-405.
  32. Olde Rikkert MG, Verhey FR, Sijben JW, et al. Differences in nutritional status between very mild Alzheimer's disease patients and healthy controls. *J Alzheimers Dis*. 2014;41(1):261-271.
  33. Czech C, Berndt P, Busch K, et al. Metabolite profiling of Alzheimer's disease cerebrospinal fluid. *PLoS One*. 2012;7(2):e31501.
  34. van Wijk N, Broersen LM, de Wilde MC, et al. Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. *J Alzheimers Dis*. 2014;38(3):459-479.
  35. Agarwal N, Sung YH, Jensen JE, et al. Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T. *Bipolar Disord*. 2010;12(8):825-833.
  36. Pooler AM, Guez DH, Benedictus R, Wurtman RJ. Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 [corrected]. *Neuroscience*. 2005;134(1):207-214.
  37. Shatenstein B, Kergoat MJ, Reid I. Poor nutrient intakes during 1-year follow-up with community-dwelling older adults with early-stage Alzheimer dementia compared to cognitively intact matched controls. *J Am Diet Assoc*. 2007;107(12):2091-2099.
  38. Crichton GE, Elias MF, Davey A, Sullivan KJ, Robbins MA. Higher HDL cholesterol is associated with better cognitive function: the Maine-Syracuse study. *J Int Neuropsychol Soc*. 2014;20(10):961-970.
  39. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. *Pharmacol Rev*. 2006;58(3):342-374.
  40. Linnebank M, Popp J, Smulders Y, et al. S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease. *Neurodegener Dis*. 2010;7(6):373-378.
  41. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. *J Neurol Neurosurg Psychiatry*. 1990;53(12):1096-1098.
  42. Donini LM, De Felice MR, Cannella C. Nutritional status determinants and cognition in the elderly. *Arch Gerontol Geriatr*. 2007;44 Suppl 1:143-153.
  43. Homocysteine studies collaboration: homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA*. 2002;288(16):2015-2022.
  44. Kloppenborg RP, Nederkoorn PJ, van der Graaf Y, Geerlings MI. Homocysteine and cerebral small vessel disease in patients with symptomatic atherosclerotic disease. The SMART-MR study. *Atherosclerosis*. 2011;216(2):461-466.
  45. Katz JE, Dlakić M, Clarke S. Automated identification of putative methyltransferases from genomic open reading frames. *Mol Cell Proteomics*. 2003;2(8):525-540.
  46. Marques S, Outeiro TF. Epigenetics in Parkinson's and Alzheimer's diseases. In: *Epigenetics: Development and Disease*. Berlin, Germany: Springer; 2013:507-525.
  47. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. *Mol Cell Neurosci*. 2005;28(1):195-204.
  48. Chan A, Tchanchou F, Rogers EJ, Shea TB. Dietary deficiency increases presenilin expression, gamma-secretase activity, and Abeta levels: potentiation by ApoE genotype and alleviation by S-adenosylmethionine. *J Neurochem*. 2009;110(3):831-836.
  49. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. *J Neurochem*. 1996;67(3):1328-1331.
  50. Imbard A, Smulders YM, Barto R, et al. Plasma choline and betaine correlate with serum folate, plasma S-adenosyl-methionine and S-adenosyl-homocysteine in healthy volunteers. *Clin Chem Lab Med*. 2013;51(3):683-692.
  51. van der Kant R, Langness VF, Herrera CM, et al. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer's disease neurons. *Cell Stem Cell*. 2019;24(3):363-375 e369.
  52. Verhage F. Intelligence and age in a dutch sample. *Human Develop*. 1965;8:238-245.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** de Leeuw FA, Tijms BM, Doorduijn AS, et al. LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: the NUDAD project. *Alzheimer's Dement*. 2020;12:e12120. <https://doi.org/10.1002/dad2.12120>